NYSE American - Nasdaq Real Time Price USD

MAIA Biotechnology, Inc. (MAIA)

1.9802

-0.0698

(-3.40%)

As of 12:09:42 PM EDT. Market Open.

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Name	Title	Pay	Exercised	Year Born
Dr. Vlad Vitoc M.B.A., M.D.	Co-Founder, President, CEO & Chairman of the Board of Directors	722.96k	--	1970
Mr. Jeffrey C. Himmelreich	Head of Finance and Principal Financial & Accounting Officer	306.5k	--	1976
Dr. Sergei M. Gryaznov Ph.D.	Chief Scientific Officer	521.66k	--	1960
Linda Moreira	Company Secretary	--	--	--

444 West Lake Street

Suite 1700

Chicago, IL 60606

United States

312-416-8592 https://maiabiotech.com

Sector:: Healthcare
Industry:
Full Time Employees:: 13

MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

MAIA Biotechnology, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events Information Not Available

April 22, 2025 at 12:00 AM UTC